EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The Reasons for Discontinuation of Infliximab Treatment in Patients with Crohns Disease A Review of Practice at NHS Teaching Hospital



The Reasons for Discontinuation of Infliximab Treatment in Patients with Crohns Disease A Review of Practice at NHS Teaching Hospital







There is little information on the reasons for discontinuing infliximab treatment in patients with Crohn's disease. The aim of this study was to document these reasons to determine if any were preventable which would allow patients to continue the therapy. Aims & Methods. A review of the medical notes was conducted at the Norfolk and Norwich University Hospital on patients with Crohn's disease treated with infliximab between 2002 2008 to determine the reasons for stopping it. A total of 65 patients were identified who had treatment with infliximab, of whom 23 (35.3%) had their therapy stopped. The reasons for discontinuation of infliximab in the 23 patients were: 47.8% side effects, 17.4% refractory disease, 13.0% achieved remission and did not receive long-term maintenance treatment, 4.34% pregnancy, 4.34% death, and unknown 13.0%. The main reasons for the discontinuation of infliximab were side effects rather than a lack of clinical response.

(PDF emailed within 1 workday: $29.90)

Accession: 036521251

Download citation: RISBibTeXText



Related references

The reasons for discontinuation of infliximab treatment in patients with Crohn's disease: a review of practice at NHS teaching hospital. Isrn Gastroenterology 2011: 672017-672017, 2011

Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment. Scandinavian Journal of Rheumatology 37(1): 6-12, 2008

Effects of antibodies to infliximab on safety and efficacy of infliximab treatment in patients with Crohns disease. Gastroenterology 122(4 Suppl 1): A 613-A 614, April, 2002

Effect of antibodies to infliximab on infusion reaction and clinical response in patients with fistulizing crohns disease receiving maintenance treatment with infliximab. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No M1598, 2003

Treatment of Crohns disease with infliximab An initial community practice experience. Gastroenterology 118(4 Suppl 2 Part 1): AGA A567, April, 2000

Treatment of Crohns disease with Infliximab does not reduce hospital attendance or admission. Gut 50(Supplement 2): A47, April, 2002

The discontinuation rate and reasons for discontinuation of implanon at the family planning clinic of University of Nigeria Teaching Hospital (UNTH) Enugu, Nigeria. Nigerian Journal of Medicine 20(4): 448-450, 2012

The safety profile of infliximab for crohns disease in clinical practice the mayo clinic experience in 500 patients. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No 64, 2003

Efficacy of infliximab in the treatment of korean patients with crohns disease. Korean Journal of Gastroenterology 54(2): 108-116, 2009

Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment. Rheumatology International 28(3): 261-269, 2007

Consistent treatment benefit with infliximab in patients with fistulizing Crohns disease. Gastroenterology 116(4 PART 2): A788, April, 1999

Treatment with infliximab in patients with fistulizing crohns disease efficacy and predictors of response. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1369, 2003

Infliximab maintenance treatment results in lower hospitalization rate in Crohns disease patients. Gastroenterology 122(4 Suppl 1): A 613, April, 2002

Transabdominal bowel sonography modifications in patients with active Crohns disease before and after infliximab treatment. Gastroenterology 120(5 Supplement 1): A 273, April, 2001

Consistency of treatment benefit with infliximab in patients with moderate-to-severe active Crohns disease. Gastroenterology 116(4 PART 2): A837, April, 1999